Better TNF? receptor blockers on the horizon
Two research teams have unraveled the complex dynamics of TNF? receptor signaling and have identified compounds that may be safer than current treatments.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
Entries by Thomas Gabrielczyk
European Commission approves ten GMOs
/in News/by Thomas GabrielczykThe European Commission has authorised ten genetically modified products.
Zambon heading to US market with 500m acquisition
/in News/by Thomas GabrielczykZambon is set to acquire respiratory company Breath Therapeutics for up to 500m to complement its respiratory pipeline and get access to the US market.
Gut microbiome boosts muscle strength
/in News/by Thomas GabrielczykSwedish researchers have demonstrated that the gut microbiome can significantly affect the proper development and strength of skeletal muscle.
Curetis lower respiratory tract panel ready for FDA clearance
/in News/by Thomas GabrielczykMolecular diagnostics expert Curetis NV has filed for US FDA clearance of Unyvero LRT to speed up diagnosis of patients with lower respiratory tract (LRT) infections.
Merck and Broad Institute announce CRISPR license agreement
/in News/by Thomas GabrielczykMerck and the Broad Institute have signed an agreement on the granting of non-exclusive intellectual property licenses to CRISPR-based genome editing.
Boehringer Ingelheim and Yuhan Corp. in US$870m NASH deal
/in News/by Thomas GabrielczykBoehringer Ingelheim has licenced a preclinical fusion protein from Korean Yuhan Corp. that activates both GLP-1R and FGF21R to treat Nonalcoholic Steatohepatitis (NASH). Boehringer Ingelheim will pay $40m upfront and […]
Smart bra set to detect breast cancer
/in News/by Thomas GabrielczykA French-Swiss research team is developing a smart bra for detecting breast cancer more accessible than through mammography.
GARDP wants five AMR breakers by 2025
/in News/by Thomas GabrielczykGARDP has called up the global community to develop and deliver five new treatments that break antimicrobial resistance (AMR) by 2025.
Sanifit raise 72.2m to push SNF472 development
/in News/by Thomas GabrielczykSanifit has bagged 72.2m in Spains largest private biotech fundraise.